There are about 1 billion flu cases annually. Since flu and COVID-19 manifest similar symptoms, tests for differentiation will be significant to enable accurate diagnosis and treatment. With the COVID-19 resurgence in the coming winter, demands for flu and the COVID-19 testing will be jumped high in parallel.

Fapon New Antibody Pairs for Influenza A/B

Product Performance | Request Sample | COVID-19 Products

They can,

Accelerate the development of Flu test kit or COVID-19/Flu combo test kit
Optimize the performance of your current Flu test kit

Their features,

Validated by the NIBSC & newly released China CDC influenza panels
Excellent reactivity & specificity
No cross-reaction to other respiratory diseases

Featured Pairs (Lateral Flow Platform)

Product	Pair No.	Catalog No.	Source	Clone	Isotype	Application	Blocker
Influenza A	Pair 1	BRCINFS102	CHO	31B4	IgG1	Coating	√
		BRJINFS102	CHO	30C6	IgG2a	Conjugate	√
	Pair 2	BRJINFS102	CHO	30C6	IgG2a	Coating	√
		BRCINFS102	CHO	31B4	IgG1	Conjugate	√
	Pair 3	BRCINFS103	CHO	30A5	IgG2a	Coating	√
		BRCINFS102	CHO	31B4	IgG1	Conjugate	√
Influenza B	Pair 1	BRNINFJ203	CHO	30D4	IgG2a	Coating	√
		BRNINFC202	CHO	30E3	IgG1	Conjugate	√
	Pair 2	BRNINFC201	Mouse	2F3	IgM	Coating	√
		BRNINFJ204	CHO	30E2	IgG2b	Conjugate	√
	Pair 3	BRNINFJ203	CHO	30D4	IgG2a	Coating	√
		BRNINFC201	Mouse	2F3	IgM	Conjugate	√

Influenza A Antibody Pairs - reactivity validated by following viral strains

Source/Virus Type	Viral Strain	Dilution Ration	Pair 1	Pair 2	Pair 3
Fapon Quality Control (Cultured-based Virus)	H1N1	1:500	C2	C3+	C3+
		1:5000	C5+	C5	C5
		1:50000	C7	C8+	C8+
	H3N2	1:500	C1	C1	C1
		1:5000	C3	C3	C3
		1:50000	C5+	C5	C5
	H5N1	1:20	C2	C3+	C3+
		1:200	C6+	C6	C6
		1:2000	C8+	C9+	C9+
	H7N9	1:20	C2+	C2	C2
		1:200	C5+	C5	C5
		1:2000	C7	C8	C8
NIBSC Standard (Inactivated Virus)	Influenza Virus Infectious NYMC X-185	20	C1+	C1+	C1+
		1000	C6	C7	C7
	Influenza Virus infectious Resvir-14 (H3N2)	20	C2	C3	C3
		1000	C8	C9	C9
	Influenza Virus infectious NIB-26 (H3N2)	20	C2+	C2	C2
		1000	C7	C9+	C9+
	Influenza Antigen A/Texas/50/2012 (NYMC X-223A)	20	C6	--	--
		1000	C9+	C9+	C9+
	Influenza Virus infectious A/Beijing/32/92 (H3N2)	20	C1	C2+	C2+
		1000	C7	C8+	C8+
	Influenza Virus infectious A/Shanghai/24/90	20	C1	C2	C2
		1000	C7	C8	C8
	Influenza Virus infectious A/Sichuan/346/98 (H3N2)	20	C1	C1	C1
		1000	C8+	C8	C8
	2019/H3N2	20	C1	C2+	C2+
	2019/H1N1	20	C1	C2	C2
	2019/H1N1	20	C1	C1	C1
	A/Brisbane/10/2007	--	Detectable		
	A/Perth/16/2009				
	A/California/7/2004				
	A/Brisbane/59/2007				
	A/Victoria/361/2011				
	A/California/7/2009				
	A/New Caledonia/20/1999				
	A/Wisconsin/67/2005				
	A/Solomon Islands/3/2006				
Others (H1N1 Virus)	A/Taiwan/1/86(BIN73)				
	A/Beijing/262/95(BIN73-2)				
	Influenza Virus infectious A/Guizhou/54/89 (H3N2)				
	Influenza Virus infectious A/Wuhan/359/95 (H3N2)				
	A/Victoria/210/2009w				
Others (H3N2 Virus)	A/Kiev/301/94(BIN74-2)				
	H3N2 A/Panama/2007/ 998IN74-1				
	A/Shandong/9/93(BIN74)				
	A/Texas/50/2012				
	A/Hiroshima/52/2005				

Influenza B AntibodyPairs - reactivity validated by following viral strains

Source/Virus Type	Viral Strain	Dilution Ration	Pair 1	Pair 2	Pair 3
Fapon Quality Control (Cultured-based Virus)	Influenza B Quality Control	30	C4	C4+	C4
		300	C6	C6+	C6
		3000	C8	C8+	C8
NIBSC Standard (Inactivated Virus)	Influenza Virus infectious NYMC BX-7	20	C4	C4++	C4+
		1000	C9	C9	C9
	Influenza virus infectious NYMC BX-39	20	C3	C3+	C3
		1000	C8+	C8+	C8+
Others (Inactivated Virus)	BY-V1908875256	32	C4	C3	C4+
		640	C6	C5	C6+
	BV-V1906106179	64	C5	C5+	C5
		640	C7	C7+	C7
	BV-V1906106180	100	C7	C7	C7
		1000	C9	C9	C9
	BV-V1906106181	100	C6	C7	C7
		1000	C8	C9	C9
	BV-V1906106182	100	C5	C6+	C6
		1000	C8	C8	C8
	B/Shanghai/361/02	--	Detectable		
	B/Malaysia/2506/2004				
	B/Massachusetts/2/2012				
	B/Wisconsin/01/2010				
	B/Tokio/53/99				
	Influenza Virus infectious B/Sichuan/379/99				
	B/Qingdao/102/91				
	B/Brisbane/60/2008				
	B/Florida/04/2006				
	B/Victoria/504/00				
	Influenza Virus infectious B/Shanghai/361/2002				



Result Interpretation: The higher the number, the lower the activity. B refers to undetectable

Cross-Reactivity

Pathogen	Type of Virus	Concentration	Application
SARS-CoV-2 S/ N Protein	Recombinant antigen	10 μg/mL	No cross-reaction with Influenza A/B
	Cultured-based virus	1:200 Dilution	
Mycoplasma pneumonia	Inactivated virus	50 μg/mL	
Parainfluenza 2		5 μg/mL	
RSV		50 μg/mL	
Adenoviridae		10 μg/mL	
Influenza B	Cultured-based virus	55 μg/mL	No cross-reaction with Influenza A
Influenza A H1N1		2 μg/mL	No cross-reaction with Influenza B
Influenza A H3N2		36 μg/mL	
Influenza A H5N1		15 μg/mL	
Influenza A H7N9		40 μg/mL	
EB virus	Inactivated virus	30 μg/mL	No cross-reaction with Influenza A/B
Mumps virus		50 μg/mL	
Varicella-zoster virus		50 μg/mL	
Human cytomegalovirus		1:10 Dilution	
Measles virus		1:10 Dilution	
Rotavirus		1:10 Dilution	

About Fapon

Fapon (en.fapon.com) is a global leading IVD raw materials & one-stop solutions company founded in 2001. As one of the top IVD companies in Asia, Fapon serves some of the multi-nation leading diagnostic companies with 800+ partnerships worldwide.

Fapon offers an unmatched product combination of reagent raw materials and IVD one-stop solutions. The company has 700+ reagent raw materials available for the application of Rapid Test, ELISA, CLIA, CMIA, Molecular Diagnostics, Biochemistry. Plus the solutions for CLIA, Immunoturbidimetry, DNA Library Preparation that provide reagent and analyzer services, Fapon satisfies customers' needs in different application scenarios.

FAPON

No.5 Hualian Road, Taiwan High-Tech Industrial Park, Songshan Lake, Dongguan, Guangdong, China